Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2026 16:01 ET | Source: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to...
March 09, 2026 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Proposed Public Offering

VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug...
March 09, 2026 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030, a...
March 09, 2026 16:01 ET | Source: Ocular Therapeutix, Inc.

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...
March 09, 2026 16:01 ET | Source: Frequency Electronics, Inc.

Frequency Electronics Announces Third Quarter Fiscal 2026 Financial Results Conference Call: Wednesday, March 11, 2026, at 4:30 PM ET

MITCHEL FIELD, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (NASDAQ: FEIM), will hold a conference call to discuss results for the third quarter of its fiscal year 2026,...
March 09, 2026 16:01 ET | Source: Design Therapeutics, Inc.

Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing...
March 09, 2026 16:01 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
March 09, 2026 16:00 ET | Source: Levi & Korsinsky, LLP

Oracle Corporation Class Action: Levi & Korsinsky Reminds Oracle Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – ORCL

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Oracle Corporation ("Oracle" or the "Company") (NYSE: ORCL) of a class action securities lawsuit. CLASS...
March 09, 2026 16:00 ET | Source: Levi & Korsinsky, LLP

Levi & Korsinsky, LLP: Institutional SNOW Holders Face Portfolio Losses from Alleged Fraud

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in Snowflake Inc. (NYSE: SNOW) during the period June 27, 2023 through February 28, 2024 may wish to evaluate...
March 09, 2026 16:00 ET | Source: Levi & Korsinsky, LLP

Levi & Korsinsky, LLP: Chronology of Events in the Inovio Pharmaceuticals Securities Class Action

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP encourages investors who suffered losses in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) to contact the firm. WHO IS AFFECTED:...